|
Patent landscape, scope, and claims: |
United States Patent 8,735,403 (Btk irreversible covalent Cys481 inhibitors): scope, claim breadth, and US patent landscape
Executive summary. US Patent 8,735,403 claims an irreversible covalent Bruton’s tyrosine kinase (BTK) inhibitor that covalently bonds to BTK cysteine 481 and is defined by multi-variable chemical structures (Formula A with narrowed sub-formulas B/C/D) plus a limited oral formulation claim. The claim set is drafted to cover a broad scaffold around an electrophilic warhead (Z) capable of covalent engagement and aryl/heteroaryl substitution patterns (R1, La) while incorporating fallback embodiments (formulas B/C/D) that tighten ring size and substitution (R6–R8) and allow additional coverage via pharmaceutically acceptable salts/solvates. From a US freedom-to-operate perspective, the key risk is that many later-generation BTK covalent inhibitors with different warheads or different binding modes may still land within claim space if they share: (i) Cys481 covalent irreversibility, (ii) the claimed electrophile class as Z, and (iii) the claimed linker/aryl architecture. For licensing and generic challenge planning, the dominant technical question is whether competing compounds are outside the specific Formula A/D variable definitions, or outside Z (electrophile scope) and the scaffold connectivity.
What does US Patent 8,735,403 claim for irreversible BTK inhibitors that covalently bind Cys481?
Core claim concept. Claim 1 is an irreversible BTK inhibitor with:
- Covalent bonding to BTK cysteine 481
- A defined multi-part chemical scaffold via Formula (A) with substituent variables:
- A (a position selector): “A is independently selected from N”
- R1: L2-(substituted/unsubstituted heteroaryl) OR L2-(substituted/unsubstituted aryl)
- R2, R3: independently H or lower alkyl
- R4: L3–X–L4–G (L3 optional; X optional; L4 optional)
- X: optional, and when present is one of a long list of linker/electrophile-containing connection units
- G: the substituent/w/warhead-connected moiety with defined R6, R7, R8 selection sets
- Salt/solvate coverage is explicit: “pharmaceutically acceptable solvate, hydrate, or salt thereof”
How “irreversible” is operationalized in claim language. The claim does not just say “irreversible.” It defines the chemistry as covalently bonds to Cys481, which in BTK patent families typically corresponds to an electrophilic warhead positioned to react with the catalytic cysteine.
Breadth drivers in claim 1 (what expands coverage):
- R1 breadth: heteroaryl or aryl with broad allowable substitutions through the “substituted or unsubstituted” language.
- Linker flexibility: L2 and the optional L3 / X / L4 allow multiple bond/linker types, including heteroatoms and sulfoxide/sulfone-like connectivity.
- R4 pathway variability: since R4 is L3–X–L4–G, the claim can cover many chemotypes if they share the same overall scaffold connectivity.
- G breadth: R6–R8 allow lower alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, including substituted variants.
- Claim 1 is structurally-defined, not limited by route of synthesis, which matters for FTO and invalidity strategies.
Breadth constrainers in claim 1 (what narrows coverage):
- The claim is constrained to the exact Formula (A) variable definitions. Even if a competitor binds Cys481 covalently, it may fall outside if:
- its scaffold cannot be mapped into R1/R4/X/L2/L4/G definitions, or
- the warhead does not fit within X and/or the way the claimed covalent site is implemented by the enumerated groups.
What are the explicit claim types beyond chemical structure (method vs formulation)?
- Chemical structure (composition-of-matter): Claims 1–12 are composition-of-matter style structure claims.
- Oral formulation: Claim 13 is an oral formulation comprising the claimed BTK inhibitor of claim 1.
No method-of-use claim is provided in the text you supplied, but the oral formulation claim creates a second patent hook for commercial product barriers even if the API structure is separately challenged.
How narrow or broad are the downstream dependent claims (2–12) that map Formula A to specific embodiments (B/C/D)?
Claim 2 depends on claim 1 and defines “the Btk inhibitor has the structure: (Formula (unknown in your excerpt))”. This is a direct embodiment lock-in and typically reduces scope to a specific compound.
Claims 3–4 are targeted narrowing:
- Claim 3: “R1 is L2-substituted aryl; L2 is a bond.”
This narrows the heteroaryl/aryl universe to aryl specifically and removes L2 heteroatom/bond variability.
- Claim 4: “R2 and R3 are independently H.”
Narrows substitution pattern at the corresponding positions.
Claim 5 is an important structural consolidation: it says Formula (A) has the structure of Formula (B), with its own variable definitions:
- Y: alkylene/substituted alkylene or 4-,5-,6-membered cycloalkylene ring
- Ra: allowed substituents on the aromatic system through a set including halogen, CF3, CN, NO2, OH, NH2, and multiple “La–(substituted/unsubstituted...)” linkers including bond, O, S, sulfoxide/sulfone-like, NH, C(O), CH2, NHC(O)O, NHC(O), C(O)NH.
- G remains defined by R6–R8 variability.
- R12: H or lower alkyl
- Salt/solvate again.
Claim 6 further narrows Formula (B):
- “Y and R12 taken together form a 6-membered heterocyclic ring.”
Claims 7–8 map to Formula (C) and introduce flexibility:
- Claim 7: Formula (B) has the structure of Formula (C)
- Claim 8: Y and R12 together form a 4-,5-, or 6-membered heterocyclic ring
This means dependent claims can cover different ring sizes while preserving the rest of the scaffold.
Claim 9 is truncated in your excerpt (“wherein G is or”), so the specific limitation cannot be reconstructed from the text provided.
Claim 10: “R6, R7, and R8 are independently H.”
This is a major narrowing on the substitution on the G substituent pocket, fixing the final group to a minimal hydrogenated form.
Claim 11 introduces an alternative structural formula:
- “irreversible inhibitor … having structure of Formula (D) …” with defined variables:
- La: CH2, O, NH or S
- Ar: optionally substituted aromatic carbocycle or aromatic heterocycle
- Y: optionally substituted alkyl/heteroalkylene/carbocyclene/heterocyclene/combination
- Z: C(O), OC(O), NHC(O), C(S), S(O)x, OS(O)x, NHS(O)x, where x is 1 or 2
- R6–R8: H, alkyl, heteroalkyl, carbocycle, heterocycle combinations
- and again the defining point: covalent bond to Cys481.
Claims 12 tightens Formula (D):
- “La is O, Ar is an aromatic carbocycle, Y is heterocyclene, Z is C(O), and R6, R7, R8 are independently H.”
What does the Z definition tell you about warhead/electrophile class coverage?
Within your text, Z enumerates multiple carbonyl-like and sulfur-oxidation states:
- C(O), OC(O), NHC(O): carbonyl and related amide/ester-like functions
- C(S): thio-carbonyl analog
- S(O)x / OS(O)x / NHS(O)x: sulfoxide/sulfone-like or sulfonamide-like connection units (x = 1 or 2)
In BTK covalent inhibitor families, the electrophile is typically a specific heteroatom-reactive motif (often a Michael acceptor or activated electrophile adjacent to the covalent cysteine). The presence of carbonyl and sulfur oxidation state options in Z suggests the claim may cover electrophile-linked linkage units, not merely aromatic substituents. Practically, this is the variable most likely to separate “in” vs “out” for competing chemotypes.
How does Claim 13 expand the patent estate into product-formulation space?
Claim 13: “An oral formulation comprising the BTK inhibitor of claim 1.”
This matters because even if an alternative scaffold is argued to avoid Formula A/D, the oral formulation claim can still capture:
- combination products built around the patented API (depending on dependency and claim scope),
- salt form substitutions (if still encompassed by claim 1’s salt/solvate language),
- and oral dosage forms that use the covered compound.
What Claim 13 does not do based on your excerpt:
- it does not add detailed excipient language,
- it does not limit release profile (immediate vs extended),
- it does not specify dosing or strength.
So Claim 13 is a broad formulation wrapper, often easier to assert than detailed process patents.
Claim-scope mapping: what features are most likely to create infringement and what features are most likely to be design-arounds?
Most infringement-sensitive elements
- Cys481 covalent bond requirement
A non-covalent BTK inhibitor that doesn’t target Cys481 covalently is likely outside claim coverage.
- Formula A/D connectivity and enumerated variable types
Even covalent inhibitors can fall out if their scaffold cannot be expressed as R1/R4/X/L2/L4/G or La/Ar/Y/Z.
- Z warhead-related enumeration
Competitors using different electrophiles may not be captured if Z cannot map to the competitor’s reactive group or its exact structural placement as defined in the formulas.
Most plausible design-around levers
- Use of a warhead motif that is not encompassed by Z
If the covalent reactive group cannot be defined by the enumerated Z options (including carbonyl-like and sulfur-oxidation-state entries as defined), it may avoid the claim.
- Change aromatic/linker architecture to fall outside R1 and/or La
Claim 1 requires a specific structural formula with defined substituent selections. Shifting connectivity (for example altering the linker atoms) can defeat literal mapping.
- Substitution pattern changes for R6–R8 and R2/R3
While claim 1 is broad, dependent embodiments (claims 3–4, 10, 12) narrow substitution. In practice, claim 1’s breadth still covers many variants, but some competitors can carve out by mapping to “impossible” combinations under the variable sets.
How strong is the patent estate around US 8,735,403 for enforcement and licensing leverage?
Strength indicators from the provided claim text
- Single, direct, composition-of-matter core claim (1) with extensive structural coverage.
- Enumerated structural fallback claims (3–4, 5–8, 10, 11–12) that can support multiple infringement theories against different competitor compounds.
- Product protection (13) for oral use.
Weakness indicators
- Without full specification text, it is not possible to evaluate enablement/written description; however, from a claim-structure standpoint the claim is highly variable and can draw interpretive fights over how well multiple chemotypes are supported by the specification.
What is the likely relationship to other BTK covalent inhibitor patent families in the US (competitive landscape risk)?
Your excerpt alone does not supply the assignee, application number, filing date, or priority chain for US 8,735,403. Without that, no exact family mapping is possible. Still, for business planning, the risk framework for BTK covalent inhibitors in the US generally turns on:
- covalent mechanism (Cys481 vs non-covalent),
- warhead chemotype (electrophile class),
- and the precise scaffold architecture (how R1/R4/X/L2/L4/G maps).
Infringement pressure tends to be highest where later competitors market BTK covalent inhibitors with:
- very similar scaffold topology,
- and electrophiles that can be argued to fall within a broad Z-like definition.
When does US 8,735,403 lose exclusivity: what matters legally in the US?
No filing/priority/issuance details are included in your input, so a legal exclusivity timeline cannot be generated from the information provided.
US patent litigation and generic-entry exposure: what does this claim set imply for Paragraph IV risk?
Claim 1’s breadth means a Paragraph IV ANDA position often requires one of these:
- non-infringement by structural mapping (Z, X, L2/La connectivity, or warhead mismatch),
- invalidity arguments (not derivable from your excerpt),
- or both.
Claim 13 means even if API non-infringement is asserted, a generic firm may still face formulation wrapper arguments unless the challenge also addresses “comprising the inhibitor of claim 1” literal scope.
Key Takeaways
- US 8,735,403 is built around an irreversible covalent BTK inhibitor targeting cysteine 481, with Formula (A) providing broad scaffold coverage via flexible variable definitions (R1, R2/R3, and the L3–X–L4–G chain).
- Dependent claims (5–8 and 11–12) narrow the scaffold into specific formula embodiments (B/C/D), providing multiple fallback claim targets against different competitor structures.
- Z is the most likely discriminating variable for warhead/electrophile coverage in infringement analysis, given its enumerated carbonyl and sulfur-oxidation state entries.
- Claim 13 extends protection to oral formulations containing the claimed API, creating a secondary product-level barrier.
FAQs
-
Which claim elements are most important to map for covalent BTK inhibitors that target Cys481?
The covalent Cys481 requirement plus the Formula A/D variable architecture, especially Z and the linker connectivity defined by X/L2/L4/La.
-
Can a non-covalent BTK inhibitor avoid infringement of US 8,735,403?
The claims require an irreversible inhibitor that covalently bonds to Cys481, so a non-covalent inhibitor is structurally outside the claimed functional definition.
-
Does the patent protect only the active ingredient or also the dosage form?
It includes an oral formulation claim (claim 13) covering oral products that comprise the claim 1 inhibitor.
-
What is the main design-around strategy for competitors?
Alter the compound so it cannot be mapped into the claimed Formula A/D definitions, most plausibly by changing the electrophile/warhead fit to Z and/or the scaffold/linker connectivity (X, L2, L4, La).
-
How do dependent claims affect enforcement against specific competitor structures?
Dependent claims provide narrower embodiments (B/C/D and fixed substituent patterns) that can support infringement arguments even if an alleged infringer attempts to differentiate on one variable set.
References (APA)
- United States Patent No. 8,735,403. (Claim text provided in user prompt).
More… ↓
⤷ Start Trial
|
